IL295654A - Setd2 inhibitors and related methods and uses, including combination therapies - Google Patents
Setd2 inhibitors and related methods and uses, including combination therapiesInfo
- Publication number
- IL295654A IL295654A IL295654A IL29565422A IL295654A IL 295654 A IL295654 A IL 295654A IL 295654 A IL295654 A IL 295654A IL 29565422 A IL29565422 A IL 29565422A IL 295654 A IL295654 A IL 295654A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- group
- cycloalkyl
- hydroxy
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978692P | 2020-02-19 | 2020-02-19 | |
| PCT/US2021/018863 WO2021168313A1 (en) | 2020-02-19 | 2021-02-19 | Setd2 inhibitors and related methods and uses, including combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295654A true IL295654A (en) | 2022-10-01 |
Family
ID=77391740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295654A IL295654A (en) | 2020-02-19 | 2021-02-19 | Setd2 inhibitors and related methods and uses, including combination therapies |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230133671A1 (https=) |
| EP (1) | EP4107157A4 (https=) |
| JP (1) | JP2023514280A (https=) |
| KR (1) | KR20220143116A (https=) |
| CN (2) | CN121695288A (https=) |
| AU (1) | AU2021224855A1 (https=) |
| BR (1) | BR112022016573A2 (https=) |
| CA (1) | CA3168069A1 (https=) |
| IL (1) | IL295654A (https=) |
| MX (1) | MX2022010171A (https=) |
| WO (1) | WO2021168313A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530844A (ja) | 2017-08-14 | 2020-10-29 | エピザイム，インコーポレイティド | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| CN111093660A (zh) * | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| US20240299352A1 (en) * | 2021-06-09 | 2024-09-12 | Epizyme, Inc. | Combination therapies with setd2 inhibitors |
| JP2024539726A (ja) * | 2021-11-01 | 2024-10-29 | エピザイム，インコーポレイティド | Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595766A (en) * | 1984-10-26 | 1986-06-17 | Ciba-Geigy Corporation | Process for the preparation of an indoline carboxylic acid |
| US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| NZ725860A (en) * | 2014-04-04 | 2019-08-30 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| WO2016040505A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Smyd inhibitors |
| CN112585119A (zh) * | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| SG11202105325QA (en) * | 2018-11-30 | 2021-06-29 | Epizyme Inc | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
-
2021
- 2021-02-19 WO PCT/US2021/018863 patent/WO2021168313A1/en not_active Ceased
- 2021-02-19 BR BR112022016573A patent/BR112022016573A2/pt unknown
- 2021-02-19 US US17/904,570 patent/US20230133671A1/en active Pending
- 2021-02-19 CA CA3168069A patent/CA3168069A1/en active Pending
- 2021-02-19 AU AU2021224855A patent/AU2021224855A1/en active Pending
- 2021-02-19 IL IL295654A patent/IL295654A/en unknown
- 2021-02-19 CN CN202511995231.5A patent/CN121695288A/zh active Pending
- 2021-02-19 MX MX2022010171A patent/MX2022010171A/es unknown
- 2021-02-19 EP EP21757967.1A patent/EP4107157A4/en active Pending
- 2021-02-19 CN CN202180028429.XA patent/CN115380033B/zh active Active
- 2021-02-19 JP JP2022549325A patent/JP2023514280A/ja active Pending
- 2021-02-19 KR KR1020227032446A patent/KR20220143116A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4107157A4 (en) | 2024-03-13 |
| MX2022010171A (es) | 2022-12-06 |
| BR112022016573A2 (pt) | 2022-11-08 |
| CA3168069A1 (en) | 2021-08-26 |
| WO2021168313A1 (en) | 2021-08-26 |
| KR20220143116A (ko) | 2022-10-24 |
| EP4107157A1 (en) | 2022-12-28 |
| CN115380033B (zh) | 2026-01-09 |
| AU2021224855A1 (en) | 2022-09-08 |
| CN121695288A (zh) | 2026-03-20 |
| CN115380033A (zh) | 2022-11-22 |
| US20230133671A1 (en) | 2023-05-04 |
| JP2023514280A (ja) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295654A (en) | Setd2 inhibitors and related methods and uses, including combination therapies | |
| US10493071B2 (en) | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | |
| IL168061A (en) | 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)- piperidine- 2, 6-dione for use in a medicament for treating and managing myelodysplastic syndromes | |
| ES2789331T3 (es) | Inhibidores de TGF-beta | |
| AU2024219653A1 (en) | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| US8759348B2 (en) | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | |
| JP2023541916A (ja) | がんの治療における、ｒａｓ阻害剤としてのインドール誘導体 | |
| US20100093691A1 (en) | Topical formulations | |
| CN113660931B (zh) | 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物 | |
| EP3283479B1 (en) | Tgf-beta inhibitors | |
| CA3138544A1 (en) | Substituted pyrrolopyridines as jak inhibitors | |
| EA005680B1 (ru) | Ингибиторы гиразы и их применение для лечения бактериальной инфекции | |
| AU2014378428A1 (en) | Condensed 5-oxazolidinone derivative | |
| CN113645964A (zh) | 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物 | |
| WO2020067735A1 (ko) | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 | |
| CA2975060A1 (en) | Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| TW202216730A (zh) | 大環化合物及其用途 | |
| EP1757602A1 (en) | Vla-4 inhibitor | |
| KR900009696A (ko) | 신규 화합물 | |
| CN118530234A (zh) | 吡啶并嘧啶衍生物及其用途 | |
| HK1140146B (en) | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | |
| HK1140146A (en) | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |